[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575379":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":27,"locations":33,"responsibleParty":49,"collaborators":21,"id":51,"slug":21,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":21,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":21,"enrollmentInfo":59,"targetDuration":21,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":21,"overallStatus":36,"whyStopped":21,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Regina Elena Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Thoracic radiotherapy-immunotherapy association in maintenance phase with atezolizumab","EXPERIMENTAL","Patients enrolled during the maintenance phase of chemoimmunotherapy treatment (standard of care) according to the IMPOWER 133 scheme which is divided as follows: 1) initial chemo-immunotherapy phase with IV treatment cycles with carboplatin AUC 5 day 1 and etoposide 100 mg\u002Fm2 days 1-3 q21 followed by a maintenance phase with immunotherapy (Atezolizumab day 1 1200 mg i.v. g1 of each cycle) until progression-toxicity.\n\nIn association with immunotherapy, all patients will undergo treatment radiotherapy with 45 Gy in 15 fractions of 3 Gy administered 5 days a week on residual disease documented on CT-PET, dose 32.5Gy (2.16Gy for 15 fractions) on lymph node sites in response complete, equivalent to (EQD2 alpha beta 10) at 30 Gy in 3 fractions.",[13,14],"Radiation: Thoracic radiotherapy","Drug: Atezolizumab 1200 mg e.v. q21",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"RADIATION","Thoracic radiotherapy","Thoracic radiotherapy using 4D technique by irradiating the initial sites of disease (primary tumor and involved hilo-mediastinal lymph nodes). The treatments must be provided with the modulated intensity technique (IMRT or VMAT), treatments with conformal technique (3DCRT) are not permitted, where necessary, the Simultaneous Integrated Boost (SIB) technique can be used.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DRUG","Atezolizumab 1200 mg e.v. q21","Radiotherapy treatment associated with Atezolizumab 1200 mg i.v. q21 administered according to clinical practice",[9],[28],{"name":29,"role":30,"phone":31,"phoneExt":21,"email":32},"Francesco Dionisi, Doctor","CONTACT","06-52663098","francesco.dionisi@ifo.gov.it",[34],{"facility":35,"status":36,"city":37,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"\"Regina Elena\" National Cancer Institute","RECRUITING","Rome","00144","Italy","IT",{"type":42,"coordinates":43},"Point",[44,45],12.51133,41.89193,{"lat":45,"lon":44},[48],{"name":29,"role":30,"phone":31,"phoneExt":21,"email":32},{"type":50,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100575379",false,"NCT06771518","Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab","Lung Microcytoma Extensive Disease: Prospective Study of Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab","Inclusion Criteria:\n\n* Histological diagnosis of lung microcytoma;\n* Age ≥18 years;\n* Performance status according to ECOG 0-2;\n* Extended disease at the time of first line oncological treatment;\n* Initial staging and restaging after chemo-immunotherapy with CT, CT-PET FDG and brain MRI;\n* In at least partial response (defined according to the Recist criteria \\[18\\]) after treatment chemoimmunotherapy according to the Impower 133 scheme;\n* Haematological, respiratory toxicity ≤ G1, other toxicities ≤ G2 at the time of treatment radiotherapy;\n* Pulmonary function tests at the time of radiotherapy treatment compatible with irradiation: FEV≥1.2 l or \\>40%, DLCO≥50%;\n* Written informed consent.\n\nExclusion Criteria:\n\n* Previous radiotherapy treatment at the thoraco-mediastinal level;\n* In disease progression after chemo-immunotherapy treatment.","ALL","18 Years",{"count":60,"type":61},37,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","Investigate the role of consolidative radiotherapy treatment at the thoraco-mediastinal level in the patient suffering from lung microcytoma - extensive disease and treated with chemo-immunotherapy with atezolizumab, in association with maintenance therapy with atezolizumab.",[67],"Small Cell Lung Cancer","2026-06-04",{"date":70,"type":71},"2026-06-05","ACTUAL",{"date":73,"type":71},"2021-12-15",{"date":75,"type":61},"2026-12-15",{"name":5,"class":6},1]